​

Sionna Therapeutics (SION) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SION Stock Forecast

Sionna Therapeutics (SION) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $27.20, with a high of $60.00 and a low of $5.00. This represents a 263.64% increase from the last price of $7.48.

SION Stock Rating

Sionna Therapeutics stock's rating consensus is Hold, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (37.50%), 4 Hold (50.00%), 1 Sell (12.50%), and 0 Strong Sell (0.00%).

Hold
Total 8 1 4 3 0 Strong Sell Sell Hold Buy Strong Buy

SION Price Target Upside V Benchmarks

TypeNameUpside
StockSionna Therapeutics263.64%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-510
Avg Price Target-$27.20$37.60
Last Closing Price$7.48$7.48$7.48
Upside/Downside-263.64%402.67%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26-110--11
Aug, 26181-111
Jul, 26181-111
Jun, 26181-111
May, 2618--110
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 10, 2026Brian AbrahamsRBC Capital$5.00$4.0822.55%-33.16%
Aug 10, 2026Wedbush$5.00$4.0623.15%-33.16%
Aug 10, 2026Stifel Nicolaus$7.00$4.0971.15%-6.42%
Aug 07, 2026Guggenheim$60.00$49.6120.94%702.14%
Aug 06, 2026Chris RaymondRaymond James$59.00$50.0217.95%688.77%
May 18, 2026Paul MatteisStifel Nicolaus$55.00$40.2236.75%635.29%
Mar 02, 2026Yatin SunejaGuggenheim$50.00$34.4045.35%568.45%
Jan 07, 2026Kambiz YazdiBTIG$58.00$37.2255.83%675.40%
Jan 05, 2026Chris RaymondRaymond James$53.00$39.2135.17%608.56%
Dec 01, 2025RBC Capital$24.00$43.57-44.92%220.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 10, 2026BTIGBuyNeutraldowngrade
Aug 10, 2026GuggenheimBuyNeutraldowngrade
Aug 10, 2026CitigroupOutperformMarket Performdowngrade
Aug 10, 2026Raymond JamesStrong BuyMarket Performdowngrade
Aug 10, 2026RBC CapitalUnderperformSector Performupgrade
Aug 10, 2026WedbushNeutraldowngrade
Aug 07, 2026GuggenheimBuyBuyhold
Aug 06, 2026Raymond JamesStrong BuyStrong Buyhold
Mar 02, 2026UBSBuyBuyhold
Feb 24, 2026CitigroupOutperforminitialise

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.40$-1.88----
Avg Forecast$-5.26$-2.65$-2.87$-3.30$-3.59$-1.95
High Forecast$-5.26$-2.58$-2.54$-2.67$-3.59$-1.95
Low Forecast$-5.26$-2.72$-3.36$-3.93$-3.59$-1.95
Surprise %-73.38%-29.06%----

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast-----$64.00M
High Forecast-----$64.00M
Low Forecast-----$64.00M
Surprise %------

Net Income Forecast

$-250M $-210M $-170M $-130M $-90M $-50M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-61.69M$-75.27M----
Avg Forecast$-223.40M$-112.48M$-114.95M$-143.05M$-152.16M$-82.77M
High Forecast$-223.40M$-109.59M$-107.92M$-113.22M$-152.16M$-82.77M
Low Forecast$-223.40M$-115.36M$-142.77M$-166.92M$-152.16M$-82.77M
Surprise %-72.39%-33.08%----

SION Forecast FAQ

Is Sionna Therapeutics stock a buy?

Sionna Therapeutics stock has a consensus rating of Hold, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Sionna Therapeutics is a neutral investment for most analysts.

What is Sionna Therapeutics's price target?

Sionna Therapeutics's price target, set by 8 Wall Street analysts, averages $27.2 over the next 12 months. The price target range spans from $5 at the low end to $60 at the high end, suggesting a potential 263.64% change from the previous closing price of $7.48.

How does Sionna Therapeutics stock forecast compare to its benchmarks?

Sionna Therapeutics's stock forecast shows a 263.64% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sionna Therapeutics over the past three months?

  • September 2026: 0% Strong Buy, 9.09% Buy, 90.91% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 9.09% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 9.09% Strong Sell.
  • July 2026: 9.09% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 9.09% Strong Sell.

What is Sionna Therapeutics’s EPS forecast?

Sionna Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.87, marking a 52.66% increase from the reported $-1.88 in 2025. Estimates for the following years are $-3.3 in 2027, $-3.59 in 2028, and $-1.95 in 2029.

What is Sionna Therapeutics’s revenue forecast?

Sionna Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, followed by $0 for 2028, and $64M for 2029.

What is Sionna Therapeutics’s net income forecast?

Sionna Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-115M, representing an 52.72% increase from the reported $-75.268M in 2025. Projections indicate $-143M in 2027, $-152M in 2028, and $-82.767M in 2029.